1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Cancer Drug News 04 APRIL 2016

Cancer Drug News 04 APRIL 2016

  • April 2016
  • -
  • Espicom Business Intelligence
  • -
  • 16 pages

Industry Trend Analysis - Transforming Cancer Treatment Paradigms Will Drive Record FDA Approvals
Industry Brief - Puma Delays Filing Neratinib NDA In Advanced BC
Industry Brief - FDA Rejects Bendeka's Orphan Drug Exclusivity In CLL/NHL
Industry Brief - EMA Validates BMS' Application For Opdivo To Treat cHL
Industry Brief - CHMP Adopts Positive Opinion On Darzalex To Treat r/r MM
Industry Brief - Argos Initiates Phase II Trial Of Lung Cancer Immunotherapy
Industry Trend Analysis - Lung Cancer Sub-Classification Drives Highly Personalised Treatment
Industry Brief - Tagrisso Approved in Japan To Treat EGFr T790M Mutation-Positive Metastatic NSCLC
Industry Brief - Xtandi Phase III Trial Initiated In mHSPCA
Industry Brief - First Patient Enrolled In Second Stage Of Onapristone Phase I/II CRPCA Trial
Industry Brief - Xofigo Approved For Sale In Japan To Treat CRPCA
Industry Brief - FDA Fast Track Designation For OXiGENE's CA4P In Advance OC
Industry Brief - EMA Validates Xilonix MAA
Industry Brief - OXiGENE Secures European ODD For CA4P To Treat NETs
Industry Brief - FDA ODD For Adaptimmune's T-Cell Therapy Targeting NY-ESO To Treat STS
Industry Brief - Aplidin To Be Filed Following Positive Results In Phase III Study
Industry Trend Analysis - Disease Interception Represents Paradigm Shift For Healthcare
Industry Trend Analysis - ADC Partnership Potential Boosted With Payload Technology
Industry Brief - Helsinn/Eisai Amend CINV Collaboration Franchise In US
Industry Brief - Zymeworks Completes Merger/Acquisition Of Kairos Therapeutics
Industry Brief - Amal Secures Funding To Develop Novel Therapeutic Cancer Vaccine
Industry Brief - Dr Reddy's Gains E7777 Rights For EU, US And Certain Emerging Markets From Eisai

Table Of Contents

Cancer Drug News 04 APRIL 2016

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests,  Opport

2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests, Opport

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-company survey from VPGMarketResearch.com contains 1,650 pages and 890 tables. The report provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein ...

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.